Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Counsyl | RCV000667940 | SCV000792469 | likely pathogenic | Ataxia-telangiectasia syndrome | 2017-06-26 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV000667940 | SCV001588743 | pathogenic | Ataxia-telangiectasia syndrome | 2021-01-13 | criteria provided, single submitter | clinical testing | For these reasons, this variant has been classified as Pathogenic. Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may create or strengthen a splice site, but this prediction has not been confirmed by published transcriptional studies. This variant has not been reported in the literature in individuals with ATM-related conditions. ClinVar contains an entry for this variant (Variation ID: 552644). This variant is not present in population databases (ExAC no frequency). This sequence change creates a premature translational stop signal (p.Tyr1763*) in the ATM gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in ATM are known to be pathogenic (PMID: 23807571, 25614872). |
Ambry Genetics | RCV002343417 | SCV002642055 | pathogenic | Hereditary cancer-predisposing syndrome | 2020-09-08 | criteria provided, single submitter | clinical testing | The c.5288_5289insGA pathogenic mutation, located in coding exon 34 of the ATM gene, results from an insertion of two nucleotides at position 5288, causing a translational frameshift with a predicted alternate stop codon (p.Y1763*). This alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. As such, this alteration is interpreted as a disease-causing mutation. |
Baylor Genetics | RCV003465480 | SCV004209492 | pathogenic | Familial cancer of breast | 2024-01-18 | criteria provided, single submitter | clinical testing | |
Myriad Genetics, |
RCV003465480 | SCV004933898 | pathogenic | Familial cancer of breast | 2024-01-25 | criteria provided, single submitter | clinical testing | This variant is considered pathogenic. This variant creates a termination codon and is predicted to result in premature protein truncation. |